Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.15, April 28, 2026

Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.

In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in marking the milestone moments of our portfolio companies.

Funding News

01/ DeepWay Raises Over $310 Million in Pre-IPO Round

Recently, Qiming Venture Partners portfolio company DeepWay secured additional major funding in its Pre-IPO round, bringing total proceeds to over $310 million — setting a record for the largest single financing round in the autonomous heavy-duty truck industry in the past five years. The proceeds will be directed primarily toward advancing DeepWay's autonomous driving R&D and the global commercialization of unmanned freight robots.

As the world's first autonomous driving technology company to build intelligent new-energy heavy-duty trucks through forward design, DeepWay has completed the standard deployment of combined assisted driving systems across its entire lineup and achieved large-scale vehicle deliveries. The company generates stable cash flow through sales of tens of thousands of vehicles, continuously reinvesting in autonomous driving R&D to create a virtuous cycle between R&D investment and commercial returns.

Going forward, DeepWay will continue to strengthen its three core strategies: in-house R&D and production of key components, intelligentization, and internationalization, accelerating the global commercial deployment of autonomous driving in freight scenarios and leading the global road freight industry toward a new era of intelligence, sustainability, and efficiency.

02/ Aureka Biotechnologies Completes $35 Million Series A+ Round

Aureka Biotechnologies, a Tech-Bio company focused on agent-driven antibody drug development and Qiming Venture Partners portfolio company, announced the completion of a $35 million Series A+ financing round. Qiming Venture Partners participated in this round alongside existing investors. To date, Aureka Biotechnologies has raised nearly $100 million across its Series A and A+ rounds.

The proceeds will be directed primarily toward advancing the development of Aureka Biotechnologies' self-developed innovative functional antibody design platform AuraIDE™, strengthening foundational models and agent capabilities, and enhancing high-throughput, high-content experimental platform infrastructure. This will further streamline the critical pipeline from project initiation, molecular design, and drug development through to translational execution, accelerating the progression of a diversified portfolio of innovative drug candidates into clinical stages.

Dr. Weian Zhao, Founder and CEO of Aureka Biotechnologies, stated: "Aureka Biotechnologies' latest agent platform, AuraIDE™, is now capable of de novo designing antibody molecules with clinical-grade functional features: precise targeting of complex epitopes, controllable activation/inhibition, multi-specificity synergy, pH-switchable responsiveness... These targets once considered 'undruggable' are being systematically conquered. Next-generation Tech-Bio infrastructure is not merely a value-add — it is a necessary condition for rewriting industry rules. This financing round will accelerate the construction of the world's first agent-experiment collaborative foundation for scalable de novo antibody design, making First-in-class no longer a matter of chance, but a repeatable, scalable, and deliverable systems capability."

Major Partnerships

01/ StepFun and Qianli Technology Enter Strategic Partnership

Recently, Qiming Venture Partners portfolio company StepFun and Qianli Technology announced a comprehensive strategic partnership. The two parties will jointly build a "native intelligent driving foundation model" from the ground up to raise the ceiling of autonomous driving models. From day one of model training, AI will be trained to directly understand the complex physical world, continuously pushing the boundaries of physical AI capabilities.

StepFun has already completed deep deployment in agent foundation models and full-modality technology: fully open-sourcing its flagship foundation model Step 3.5 Flash for agent scenarios, and building a leading full-modality model matrix with end-cloud collaboration. Focusing on the "AI + terminals" direction, we will embed large models into more terminal devices, making human interaction with the physical world simpler and smarter.

02/ RuiNing Biotech Enters Strategic Partnership with Nanjing Chia Tai Tianqing

Recently, Qiming Venture Partners portfolio company RuiNing Biotech signed a strategic cooperation agreement with Zhengda Weikang, a subsidiary of Nanjing Chia Tai Tianqing. The two parties will jointly advance the commercialization of Respacio® Absorbable Spacer Hydrogel, a radiation protection and isolation product for cervical cancer treatment, in the Chinese mainland market.

As a benchmark enterprise in China's medical hydrogel sector, RuiNing Biotech has overcome multiple "bottleneck" challenges and successfully developed Respacio® Absorbable Spacer Hydrogel, demonstrating robust independent innovation capabilities. Under the agreement, this partnership focuses on resource integration and complementary strengths, with both parties conducting deep collaboration around market expansion, terminal network coverage, and improving patient access. Leveraging Zhengda Weikang's mature commercial platform, the partnership will accelerate the product's journey from regulatory approval to clinical application, effectively addressing unmet clinical needs in the relevant disease area.

Product Launch

DeepWise Releases AI Scientific Document Parsing Engine Uni-Parser

Recently, Qiming Venture Partners portfolio company DeepWise released Uni-Parser, a self-developed next-generation multimodal scientific document parsing engine. It provides one-stop automated parsing from "complex scientific PDFs" to "structured data," and is one of the few industrial-grade systems capable of simultaneously processing molecular structures, mathematical formulas, and complex tables, achieving industry-leading performance in scientific literature and patent parsing scenarios.

Uni-Parser has achieved true industrial-grade large-scale production capability and pioneered a hierarchical tree-structured document parsing paradigm. In terms of performance, Uni-Parser demonstrates industry-leading capabilities in chemical structure parsing tasks, stably handling complex structural forms such as inline molecules and table-contained molecules, significantly breaking through the capability bottlenecks of traditional OCR and multimodal large models in dense chemical expression parsing. In self-built benchmark tests for scientific literature and patent parsing (Uni-Parser Benchmark), Uni-Parser achieved significantly superior overall performance compared to mainstream document parsing methods, with clear advantages particularly in scientific text, mathematical formulas, molecular localization and recognition, and reading order of complex scientific layouts. Uni-Parser also provides standardized API service capabilities, enabling one-click access to complete parsing functionality via interface calls without local environment configuration or complex dependency deployment.

Furthermore, based on Uni-Parser, DeepWise constructed and open-sourced the scientific multimodal dataset OmniScience, released on Hugging Face, which reached the trending list and achieved tens of thousands of downloads within days of launch.

R&D Progress

01/ Biren Technology Completes DeepSeek-V4 Adaptation Verification and Optimization on Bili™ 166 Series

Recently, Qiming Venture Partners portfolio company Biren Technology (06082.HK) announced that the preview version of the new DeepSeek-V4 model series has officially launched and been open-sourced simultaneously. Leveraging its mature BIRENSUPA™ software stack and self-developed GPU full-stack agent "AIModelMaster," Biren Technology rapidly completed the adaptation verification and optimization of DeepSeek-V4 on its flagship general-purpose GPU Bili™ 166 series products, fully unleashing the products' compute density and bandwidth advantages to comprehensively empower GenAI inference acceleration.

Biren Technology's adaptation focused on DeepSeek-V4's core technical characteristics, conducting deep optimization around MoE architecture, sparse attention, FP8 mixed precision, and other key modules. Leveraging the BIRENSUPA™ software stack and AIModelMaster, the company completed model validation, customized operator development, and end-to-end performance tuning, achieving "same-day adaptation, next-day optimization" rapid delivery.

Biren Technology remains committed to a fully self-developed full-stack approach, achieving independent control of core technologies from microarchitecture and instruction sets to software stacks. The company has recently completed comprehensive adaptation of leading large models including the DeepSeek V/R series, Tencent Hunyuan series, Moonshot AI Kimi series, Alibaba Qwen series, MiniMax M2 series, Zhipu AI GLM series, StepFun Step series, and OpenMOSS MOVA series, covering the full matrix of language, multimodal, and AIGC categories.

02/

Abbisko Pharma Presents Six Research Advances

Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) recently presented six latest preclinical and translational medicine research achievements in poster format at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego, United States. The research covers multiple core innovation directions, including the pan-KRAS inhibitor ABSK211, the fourth-generation EGFR inhibitor ABK-EGFR-1, the CDK4-selective inhibitor ABK-CDK4, the PRMT5-MTA synergistic inhibitor ABSK131, and a study using ctDNA technology to elucidate resistance mechanisms to the FGFR2/3 inhibitor ABSK061.

ABSK211 is a highly potent, highly selective small-molecule pan-KRAS inhibitor with good oral bioavailability developed by Abbisko Pharma, demonstrating broad-spectrum inhibitory activity against multiple KRAS mutations and aiming to address unmet clinical needs for patients with KRAS-driven tumors. ABK-EGFR-1 is a fourth-generation EGFR inhibitor targeting the EGFR C797S resistance mutation developed by Abbisko Pharma, combining high selectivity with central nervous system (CNS) penetration capabilities to address key clinical challenges following resistance to third-generation EGFR inhibitors. ABK-CDK4 is a CDK4-selective inhibitor independently developed by Abbisko Pharma, combining high selectivity with blood-brain barrier penetration as a small-molecule CDK4 inhibitor, aiming to provide differentiated treatment options through precise CDK4 targeting, reduced CDK6-related toxicity, and expanded therapeutic potential for patients with brain metastases. ABSK131 is a highly potent, highly selective small-molecule PRMT5-MTA synergistic inhibitor developed by Abbisko Pharma, targeting MTAP-deleted tumors, a specific molecular subtype, and has currently entered clinical studies. ABSK061 is a highly active, highly selective small-molecule FGFR2/3 inhibitor independently developed by Abbisko Pharma, demonstrating good therapeutic potential in multiple solid tumors driven by FGFR aberrant activation, showing good efficacy and safety in Phase I clinical studies, and currently advancing to Phase II clinical studies in gastric cancer.

03/

Gan & Lee Pharmaceuticals' GLR1059 Injection Receives Clinical Trial Approval from National Medical Products Administration

Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that it recently received a Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the initiation of clinical trials for GLR1059 injection for the treatment of advanced solid tumors. GLR1059 injection is a Class 1 therapeutic biological product and an antibody-drug conjugate (ADC) in lyophilized powder for injection, independently developed by Gan & Lee Pharmaceuticals. This approval establishes an important foundation for subsequent clinical development of the product, with the potential to bring new treatment options to patients with advanced cancer, improving quality of life and prognosis.

GLR1059 injection demonstrated dual superiority in efficacy and safety in preclinical studies, representing a potential best-in-class drug that could provide safer and more effective treatment options for Nectin-4-positive cancer patients, addressing unmet needs in this field. Additionally, GLR1059's payload belongs to a different series from the widely used monomethyl auristatin E (MMAE) and topoisomerase inhibitors (TOPi), giving it the potential to overcome resistance in patients who have developed resistance to MMAE and TOPi ADCs.

04/

MediLink Therapeutics Presents Two Innovative Research Achievements

At AACR 2026, Qiming Venture Partners portfolio company MediLink Therapeutics presented its latest results for YL413 and YL252.

YL413 is an innovative dual-payload ADC that, while retaining MediLink's characteristic "tumor microenvironment cleavage mechanism," combines the dual action of topoisomerase I inhibitor and tubulin inhibitor. In vivo experiments showed that YL413 demonstrated excellent efficacy in both trastuzumab deruxtecan (Enhertu) resistant models and HER2 low-expression models, showing potential to overcome resistance to existing HER2 ADC drugs. YL252 is a multifunctional ADC targeting multiple pathways, built on MediLink's TMALIN® platform, combining immunomodulatory and anti-angiogenic functions, capable of precisely releasing payloads in tumor cells and the tumor microenvironment. In vitro and in vivo studies showed that YL252 not only possesses excellent tumor-killing effects and good tolerability, but also effectively blocks VEGF/VEGFR and PD-1/PD-L1 signaling pathways. Preclinical data support subsequent development of YL252 in multiple tumor indications.

Technology Strength

WeRide Sets New Record with Consecutive Wins in China Intelligent Driving Competition

Recently, at the Wuhu stop of the 2nd China Intelligent Driving Competition hosted by D1EV.COM, the Chery Exeed Sterra ET equipped with the one-stage end-to-end assisted driving solution jointly developed by Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD, 0800.HK) and Bosch Group claimed first place with a dominant margin of over 10 points ahead of the second-place finisher. With this, WeRide's WRD 3.0 one-stage end-to-end technology has achieved the first and only "four-peat" in the history of the China Intelligent Driving Competition, once again demonstrating to the industry WeRide's断层式领先 —断层式领先断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式断层式